Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesWhat is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy
Indian Journal of Urology, 06/29/09
Maheshwari R et al. - Study concludes that adjuvant chemotherapy does not improve either cancer specific survival (CSS) or overall survival (OS) in high-risk bladder cancer patients.
Methods- Aim was to investigte if pts with pathologically staged tumors with evidence of metastatic disease may benefit from systemic therapy
- Within a study group of 958 pts treated with radical cystectomy (RC), 274 (29.0%) pts with a high risk of progression were identified
- Of these, 129 (46.6%) received adjuvant chemotherapy (ACHT):
- 103 pts received Methotrexate, Vincristine, Adriamycin, Cyclophosphamide (MVAC)
- 26 pts received Gemcetabine and Cis-platin (GC)
- These pts were then matched with the remaining pts who were unexposed to ACHT
- Exact matches were made for age year of surgery, pT stage, tumor grade, pN stage and lymphovascular invasion (LVI)
- Median f/u in event-free pts was 2.4 yrs; cancer-specific mortality was documented in 115 pts (41.5%)
- Median actuarial CSS: 5.3 yrs; in the overall cohort, the mean CSS probabilities were 64.2, 51.3, and 37.7% respectively, at 2, 5 and 10 yrs after RC
- Median actuarial OS was 3.7 yrs ; OS probabilities were 60.7, 44.9 and 25.9%, respectively, at 2, 5 and 10 yrs after RC in the overall cohort
- No difference in age, year of surgery, tumor grade, tumor stage, rate of LVI, and rate of lymph node invasion between the groups
- CSS and OS were not different between the overall cohort and the matched cohort
- No difference in CSS or in OS between the groups
- No difference in the CSS or in the OS between the 2 ACHT regimens
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Palliative Oncology: Thalidomide
American Journal of Hospice and Palliative Medicine, 10/21/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Aspirin use associated with lower colorectal cancer mortality
American Pharmacists Association, 10/14/09
Sponsor
Article Search
Sponsor